- Topline data expected to be presented at a scientific conference in May 2022
- Independent data shows ~5.4M outpatient colonoscopies are performed in EU annually1
- New study data expected to further aid in commercial adoption
FORT LAUDERDALE, Fla., April 21, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the final patient has been enrolled in the European Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using both a low volume preparation with limited diet restrictions and the Pure-Vu System. The Company expects to announce topline data from the study at a leading scientific conference in May 2022.
“Completing patient enrollment in the EU study is a key milestone for our strategy to generate additional clinical data for the Pure-Vu System and support its commercial adoption, as well as build awareness to support a potential entrance into Europe,” commented Tim Moran, Chief Executive Officer of Motus GI. “The EU study is designed to evaluate the Pure-Vu System’s ability to help patients that have a history of poor bowel preparation that has caused failed and repeated procedures. We expect this study will show our system is effective in allowing procedures for these patients to proceed, which would be valuable to patients, physicians and healthcare facilities by avoiding the loss of time and costs associated with failed and repeat procedures and the potential for missed pathology that may lead to interval cancers.”
The EU study enrolled a total of 44 patients who have a history of poor bowel preparation and are scheduled for either screening, diagnostic, or surveillance colonoscopy across two sites, including the Radboud University Medical Center (Netherlands), and GastroZentrum Lippe, Bad Salzuflen in concert with the University Medical Center Mainz (Germany). The patients were prescribed a low volume bowel preparation, with just 2x150ml picoprep. The patients were also allowed to eat a low fiber diet for two days prior to the colonoscopy as opposed to the typical clear liquid diet the day before a colonoscopy. The patients then received intra-procedural bowel cleansing with the Pure-Vu System. The primary endpoint for the study is improvement of the bowel preparation from baseline to post procedure as assessed by the Boston Bowel Preparation Scale (BBPS), which assesses the cleanliness of each of the three segments of the colon on a zero to three scale and requires a minimum score of two or better per segment to be considered adequately prepped. The study is also looking at key clinical endpoints related to the quality of the examination including detection of critical pathology in the colon.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
1 According to 2019 iData Research Inc.
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, the expected timing and results of the feasibility study, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, business strategies, potential grow opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s quarterly and annual reports filed with the Securities and Exchange Commission, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.